Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Biomx Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PHGE
American
8731
https://www.biomx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Biomx Inc
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
- Apr 23rd, 2024 12:00 pm
BiomX Announces the Appointment of Susan Blum to its Board of Directors
- Apr 18th, 2024 12:00 pm
Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now
- Apr 5th, 2024 1:55 pm
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
- Apr 4th, 2024 11:49 am
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Apr 3rd, 2024 10:30 am
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
- Mar 27th, 2024 10:30 am
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
- Mar 18th, 2024 10:30 am
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
- Mar 6th, 2024 12:30 pm
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
- Jan 4th, 2024 1:00 pm
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
- Nov 30th, 2023 9:15 pm
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
- Nov 29th, 2023 11:30 am
BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 14th, 2023 11:30 am
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference
- Oct 27th, 2023 12:00 pm
BiomX Announces the Appointment of Edward L. Williams to its Board of Directors
- Oct 18th, 2023 12:00 pm
BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
- Oct 4th, 2023 10:34 am
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023
- Sep 7th, 2023 1:00 pm
BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 8:05 pm
BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 9th, 2023 10:30 am
BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023
- Aug 2nd, 2023 8:30 pm
NYSE American Initiates Delisting Proceedings for BiomX Warrants
- Jun 8th, 2023 9:00 pm
Scroll